Tenpoint receives £10m from British Patient Capital
The company aims to deliver therapies that provide benefits to patients affected by eye diseases
Read Moreby John Pinching | Jul 12, 2023 | News | 0
The company aims to deliver therapies that provide benefits to patients affected by eye diseases
Read Moreby John Pinching | Feb 17, 2023 | News | 0
Company has reported strong momentum among the early-stage businesses it invested in last year
Read Moreby John Pinching | Jul 29, 2022 | News | 0
Investment is a key boost to the acceleration of treatment access in the UK
Read Moreby John Pinching | Mar 25, 2022 | News | 0
The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices
Read Moreby Lucy Parsons | Jun 22, 2021 | News | 0
An extra £40m will go toward enhancing mental health services for children and young people
Read Moreby Lucy Parsons | Apr 30, 2021 | News | 0
Health Secretary reveals government’s plans for UK life sciences ‘transformation’
Read Moreby Lucy Parsons | Mar 11, 2021 | News | 0
Proceeds will be used to ‘more than triple’ UK biotech’s manufacturing capabilities
Read Moreby Lucy Parsons | Jan 19, 2021 | News | 0
Industry’s GVA has increased to $1.8bn according to new ABPI Scotland report
Read Moreby Selina McKee | Sep 27, 2019 | News | 0
Hospitals to get upgraded machines under the plans
Read Moreby Anna Smith | Sep 11, 2019 | News | 0
Thousands of NHS patients could receive faster diagnosis and better treatment for life-changing diseases like cancer, dementia and Parkinson’s.
Read Moreby Anna Smith | Jul 22, 2019 | News | 0
The funding is available as part of the Government’s modern Industrial Strategy.
Read Moreby Anna Smith | Jul 10, 2019 | News | 0
ABPI chief said that the investment from companies is “excellent news at a time of economic uncertainty and signals the strength of the sector in the UK.”
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
